Frontiers in CNS Drug Discovery

Author(s): Getaw Worku Hassen, Leo Kesner, Alfred Stracher and Abraham Shulman

DOI: 10.2174/9781681084435117030004

Calpain Inhibition: A Potential Therapeutic Target for Neurodegenerative and Neuromuscular Disorders

Pp: 33-71 (39)

Buy Chapters

* (Excluding Mailing and Handling)

  • * (Excluding Mailing and Handling)

Abstract

SHS investigation development is considered from the geographical and historical viewpoint. 3 stages are described. Within Stage 1 the work was carried out in the Department of the Institute of Chemical Physics in Chernogolovka where the scientific discovery had been made. At Stage 2 the interest to SHS arose in different cities and towns of the former USSR. Within Stage 3 SHS entered the international scene. Now SHS processes and products are being studied in more than 50 countries.

Abstract

Proteases are involved in different neurodegenerative and neuromuscular disorders. The role of protease inhibitors as therapeutic agents has been the matter of intense research. Given the role of proteases in these diseases, it is appealing to develop a single agent as a “magic bullet” that would target all the disease states. Calpain inhibitors have been tested with success in animal models of human diseases. In this review, we summarize the role of calpain in selected neurodegenerative and neuromuscular diseases. We describe the various instances in which calpain has been implicated and discuss the results of calpain inhibition in each disease entity as well as how targeted calpain inhibition could be beneficial. The focus of this review is to highlight the potential role of targeted inhibition as a therapeutic option and to introduce three newer calpain inhibitors with unique characteristics.

Recommended Chapters

We recommend

Favorable 70-S: Investigation Branching Arrow

Authors:Bentham Science Books